Skip to main content
Skip to footer
Home
News Channels
Antibodies
Proteins and Peptides
Vaccines
DNA RNA and Cells
Small Molecules
More News
All News
Reports
Press Room
Contact Us
About Us
All Categories
Antibodies
DNA RNA and Cells
More News
Proteins and Peptides
Small Molecules
Vaccines
Any Word
All Words
Exact Phrase
CAR T-Cells
Apr 2024
Claudin 18.2-Targeted Immunotherapeutics – a Competitor Analysis
430,00€
Apr 2024
Report Package: Claudin 18.2-Targeted Immunotherapeutics
2.150,00€
Jan 2024
GPC3-Targeted Immunotherapy Pipeline Review
300,00€
Nov 2023
DLL3-Targeted Immunotherapy Candidates Pipeline Review
200,00€
Nov 2023
B7-H3-Targeted Immunotherapy Candidates Pipeline Review
300,00€
Sep 2023
PSMA-Targeted Therapy Pipeline Review
400,00€
Sep 2023
Mesothelin-Targeted Immunotherapy Pipeline Review
300,00€
Aug 2023
Claudin 18.2-Targeted Immunotherapy: a landscape analysis of stakeholders, drug modalities, pipeline and business opportunities from an industry perspective
2.150,00€
Aug 2023
Folate Receptor alpha (FRα) Targeted Therapy Pipeline Review
300,00€
Feb 2023
CAR-M Industry Landscape Analysis: Chimeric Antigen Receptor-Macrophage (CAR-M) Stakeholders, Technologies, Pipeline, Partnering and Financing
1.800,00€
1
2
→
Any Word
All Words
Exact Phrase
Report categories
Antibody & Protein Sales
Antibody Technologies
Biosimilar Antibodies & Proteins
CAR T-Cells
Drug the Undruggable Technologies
Immuno-Oncology
mRNA Vaccines & Therapeutics
NK Cells & CAR Macrophages
Pipeline Database
RNA-Targeted Therapeutics
Target Pipelines
TCR T-Cells and Antibodies
Therapeutic Antibodies
Therapeutic Proteins & Peptides
